Ipamorelin peptide Canada from Maple Research Labs delivers 5mg of high-purity growth hormone secretagogue for qualified research applications.
Ipamorelin peptide Canada: a selective growth hormone secretagogue pentapeptide developed for research into pulsatile GH release mechanisms. Available from Maple Research Labs with a published 99.68% HPLC-UV result for a tested sample; the third-party COA is linked on this page.
Product Specifications
- CAS Number: 170851-70-4
- Molecular Formula: C38H49N9O5
- Molecular Weight: 711.85 g/mol
- Tested 5mg sample: 99.68% HPLC-UV relative-area purity (report DBAV-IPA-5-052926). This report does not establish the lot currently shipping.
- Form: Lyophilized powder
- Quantity: 5mg per vial
Ipamorelin Peptide Canada Research Summary
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that acts on the ghrelin/GHS receptor (GHSR). First described by Novo Nordisk researchers, ipamorelin is notable for its selectivity in stimulating growth hormone release without significantly affecting other pituitary hormones such as ACTH, prolactin, FSH, LH, or TSH in preclinical models. This selectivity profile has made the ipamorelin peptide Canada product a widely used research tool in neuroendocrine studies.
Published receptor-binding research describes ipamorelin as a selective GHS-R1a agonist compared with earlier secretagogues such as GHRP-6 and GHRP-2. This selectivity has been attributed to its specific binding characteristics at the GHSR-1a receptor.
Mechanism of Action Research
Ipamorelin acts as an agonist at the growth hormone secretagogue receptor (GHSR-1a), the same receptor targeted by the endogenous peptide ghrelin. Binding at this receptor triggers intracellular calcium signaling cascades in somatotroph cells of the anterior pituitary, leading to growth hormone release in a pulsatile pattern that mimics physiological secretion in animal models.
Published research has compared ipamorelin to other GHSR agonists including GHRP-6, GHRP-2, and hexarelin.
Research has also investigated ipamorelin in combination with GHRH analogs such as CJC-1295, exploring potential synergistic effects on GH secretion patterns in preclinical settings. These combination studies have examined whether simultaneous stimulation of both GHRH and GHSR pathways produces amplified or qualitatively different GH release patterns compared to either compound alone.
Preclinical Study Summary
Ipamorelin has been investigated in multiple preclinical contexts including neuroendocrine research, bone density studies in ovariectomized rat models, and gastrointestinal motility research. Published studies span several research groups and have consistently reported its selectivity profile as a distinguishing characteristic within the GH secretagogue class.
All findings referenced are from preclinical research. No claims regarding human therapeutic applications are made or implied.
References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 (PubMed)
Ipamorelin Peptide Canada Quality Assurance
Third-party certificates of analysis for tested samples are published on our COA page. Read the applicable report for its tested compound, size, method and results. Read the applicable report for any reported retention time, method-specific relative-area purity and separately measured content. These results apply to its tested sample. Published sample reports alone do not establish the lot or analysis of a specific supplied vial. Vials do not carry printed lot or batch numbers. Review the individual report for the analyses actually performed. HPLC-UV purity alone does not establish sequence, cyclization, oxidation state or shipping-unit consistency.
Storage and Handling
Store at -20C lyophilized. Avoid freeze-thaw cycles and direct light exposure.
Shipping
In-stock orders paid by 2 PM PT (Mon–Fri) ship the same business day, from BC with tracking.
Certificate of Analysis (COA)
| Testing Laboratory | Independent third-party laboratory |
| Report Number | DBAV-IPA-5-052926 |
| Lot Number | 5866 |
| Purity (HPLC-UV) | 99.68% |
| Content / Fill Accuracy | 5.36mg measured / 5.00mg expected (107.2%) |
| Date Tested | June 9, 2026 |
| Download COA | Download Full COA (PDF) |
For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.
Related Research Articles
- Ipamorelin vs CJC-1295: GHRP vs GHRH Research
- Ipamorelin vs Tesamorelin: Understanding the Differences
- Certificates of Analysis (COA) Documentation
- Browse All Research Peptides
Frequently Asked Questions
What is the CAS number for Ipamorelin?
The CAS registry number for Ipamorelin is 170851-70-4. It is a synthetic pentapeptide growth hormone secretagogue.
What purity does Maple Research Labs Ipamorelin achieve?
The linked report lists sample identifier 5866 and a reported HPLC purity of 99.68%; consult that report for its tested size and analytical scope. This does not by itself establish the lot currently shipping.
How should Ipamorelin be stored?
Lyophilized: -20C for 24+ months. Ipamorelin is a stable pentapeptide under standard conditions.
Related Research Peptides from Maple Research
Researchers may also be interested in CJC-1295/Ipamorelin Blend, CJC-1295 (No DAC), and Tesamorelin 5MG. See each product’s available analytical documentation and tested-sample results in the COA index. In-stock orders paid by 2 PM PT (Mon–Fri) ship the same business day, from BC with tracking.
Join the research list
New arrivals, current pricing, and research breakdowns, every few days. Unsubscribe anytime.
Maple 







